One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Eagle Pharmaceuticals Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Eagle Pharmaceuticals Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Eagle Pharmaceuticals Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Eagle Pharmaceuticals Inc (EGRX)

Before we jump into Eagle Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company?s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Want to learn more about Eagle Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eagle Pharmaceuticals Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Eagle Pharmaceuticals Inc’s Stock Price as of Market Close

As of September 07, 2023, 4:00 PM CST, Eagle Pharmaceuticals Inc’s stock price was $16.16.

Eagle Pharmaceuticals Inc is down 4.77% from its previous closing price of $16.97.

During the last market session, Eagle Pharmaceuticals Inc’s stock traded between $16.84 and $17.54. Currently, there are 13.09 million shares of Eagle Pharmaceuticals Inc stock available for purchase.

Eagle Pharmaceuticals Inc’s price-earnings (P/E) ratio is currently at 18.6, which is low compared to the Pharmaceuticals industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Eagle Pharmaceuticals Inc Stock Price History

Eagle Pharmaceuticals Inc’s (EGRX) price is currently down 4.66% so far this month.

During the month of September, Eagle Pharmaceuticals Inc’s stock price has reached a high of $18.16 and a low of $15.94.

Over the last year, Eagle Pharmaceuticals Inc has hit prices as high as $40.85 and as low as $16.19. Year to date, Eagle Pharmaceuticals Inc’s stock is down 68.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Eagle Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 06, 2023, there were 0 analysts who downgraded Eagle Pharmaceuticals Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Eagle Pharmaceuticals Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Eagle Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eagle Pharmaceuticals Inc (EGRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Eagle Pharmaceuticals Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of September 06, 2023, Eagle Pharmaceuticals Inc has a weighted four-quarter relative price strength of -15.50%, which translates to a Momentum Score of 23 and is considered to be Weak.

Want to learn more about how Eagle Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eagle Pharmaceuticals Inc Stock Price: Bottom Line

As of September 7, 2023, Eagle Pharmaceuticals Inc’s stock price is $16.16, which is down 4.77% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Eagle Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.